The Risk of Venous Thromboembolism, Myocardial Infarction, and Ischemic Stroke Among Women Using the Transdermal Contraceptive System Compared With Women Using Norgestimate-containing Oral Contraceptives With 35 mcg Ethinyl Estradiol

Trial Profile

The Risk of Venous Thromboembolism, Myocardial Infarction, and Ischemic Stroke Among Women Using the Transdermal Contraceptive System Compared With Women Using Norgestimate-containing Oral Contraceptives With 35 mcg Ethinyl Estradiol

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs Ethinylestradiol/norelgestromin; Ethinylestradiol/norgestimate
  • Indications Pregnancy
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 15 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 08 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top